Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events.

Naidoo J, Zhang J, Lipson EJ, Forde PM, Suresh K, Moseley KF, Mehta S, Kwatra SG, Parian AM, Kim AK, Probasco JC, Rouf R, Thorne JE, Shanbhag S, Riemer J, Shah AA, Pardoll DM, Bingham CO, Brahmer JR, Cappelli LC.

J Natl Compr Canc Netw. 2019 Jun 1;17(6):712-720. doi: 10.6004/jnccn.2018.7268.

PMID:
31200355
2.

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis.

Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, Kendra K, Ricciuti B, Chiari R, De Giglio A, Sleiman J, Funchain P, Wills B, Zhang J, Naidoo J, Philpott J, Gao J, Subudhi SK, Wang Y.

J Clin Oncol. 2019 Jun 4:JCO1900320. doi: 10.1200/JCO.19.00320. [Epub ahead of print]

PMID:
31163011
3.

Genome-wide cell-free DNA fragmentation in patients with cancer.

Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, Jensen SØ, Medina JE, Hruban C, White JR, Palsgrove DN, Niknafs N, Anagnostou V, Forde P, Naidoo J, Marrone K, Brahmer J, Woodward BD, Husain H, van Rooijen KL, Ørntoft MW, Madsen AH, van de Velde CJH, Verheij M, Cats A, Punt CJA, Vink GR, van Grieken NCT, Koopman M, Fijneman RJA, Johansen JS, Nielsen HJ, Meijer GA, Andersen CL, Scharpf RB, Velculescu VE.

Nature. 2019 Jun;570(7761):385-389. doi: 10.1038/s41586-019-1272-6. Epub 2019 May 29.

PMID:
31142840
4.

Lung cancer and family-centered concerns.

Feliciano J, Chang A, Venkatraman D, Brooks S, Zagaja C, Ettinger D, Hann C, Naidoo J, Voong R, Hales R, Turner M, Peterson V, Bodurtha J.

Support Care Cancer. 2019 May 7. doi: 10.1007/s00520-019-04839-5. [Epub ahead of print]

PMID:
31065838
5.

Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.

Voong KR, Hazell SZ, Fu W, Hu C, Lin CT, Ding K, Suresh K, Hayman J, Hales RK, Alfaifi S, Marrone KA, Levy B, Hann CL, Ettinger DS, Feliciano JL, Peterson V, Kelly RJ, Brahmer JR, Forde PM, Naidoo J.

Clin Lung Cancer. 2019 Mar 28. pii: S1525-7304(19)30068-3. doi: 10.1016/j.cllc.2019.02.018. [Epub ahead of print]

PMID:
31031204
6.

Management of Immunotherapy-Related Toxicities, Version 1.2019.

Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Hoffner B, Hoimes CJ, Lacouture M, Locke F, Lunning M, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wahidi M, Wang Y, Johnson-Chilla A, Scavone JL.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289. doi: 10.6004/jnccn.2019.0013.

PMID:
30865922
7.

Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.

Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, Bartlett BR, Aulakh LK, Sidhom JW, Zhu Q, Sears CL, Cope L, Sharfman WH, Thompson ED, Riemer J, Marrone KA, Naidoo J, Velculescu VE, Forde PM, Vogelstein B, Kinzler KW, Papadopoulos N, Durham JN, Wang H, Le DT, Justesen S, Taube JM, Diaz LA Jr, Brahmer JR, Pardoll DM, Anders RA, Housseau F.

J Immunother Cancer. 2019 Mar 6;7(1):63. doi: 10.1186/s40425-019-0547-7.

8.

Diagnostic accuracy of the Xpert CT/NG and OSOM Trichomonas Rapid assays for point-of-care STI testing among young women in South Africa: a cross-sectional study.

Garrett N, Mitchev N, Osman F, Naidoo J, Dorward J, Singh R, Ngobese H, Rompalo A, Mlisana K, Mindel A.

BMJ Open. 2019 Feb 19;9(2):e026888. doi: 10.1136/bmjopen-2018-026888.

9.

Development of a novel frameless skull-mounted ball-joint guide array for use in image-guided neurosurgery.

Sudhakar V, Mahmoodi A, Bringas JR, Naidoo J, Kells A, Samaranch L, Fiandaca MS, Bankiewicz KS.

J Neurosurg. 2019 Feb 15:1-10. doi: 10.3171/2018.10.JNS182169. [Epub ahead of print]

PMID:
30771782
10.

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.

Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, Bartlett BR, Aulakh LK, Sidhom JW, Zhu Q, Sears CL, Cope L, Sharfman WH, Thompson ED, Riemer J, Marrone KA, Naidoo J, Velculescu VE, Forde PM, Vogelstein B, Kinzler KW, Papadopoulos N, Durham JN, Wang H, Le DT, Justesen S, Taube JM, Diaz LA Jr, Brahmer JR, Pardoll DM, Anders RA, Housseau F.

J Immunother Cancer. 2019 Feb 11;7(1):40. doi: 10.1186/s40425-018-0492-x. Erratum in: J Immunother Cancer. 2019 Mar 6;7(1):63.

11.

Cardiovascular toxicities associated with immune checkpoint inhibitors.

Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, Lyon AR, Padera RF, Johnson DB, Moslehi J.

Cardiovasc Res. 2019 Apr 15;115(5):854-868. doi: 10.1093/cvr/cvz026. Erratum in: Cardiovasc Res. 2019 Apr 15;115(5):868.

PMID:
30715219
12.

Kinetics and MR-Based Monitoring of AAV9 Vector Delivery into Cerebrospinal Fluid of Nonhuman Primates.

Ohno K, Samaranch L, Hadaczek P, Bringas JR, Allen PC, Sudhakar V, Stockinger DE, Snieckus C, Campagna MV, San Sebastian W, Naidoo J, Chen H, Forsayeth J, Salegio EA, Hwa GGC, Bankiewicz KS.

Mol Ther Methods Clin Dev. 2018 Dec 8;13:47-54. doi: 10.1016/j.omtm.2018.12.001. eCollection 2019 Jun 14.

13.

PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer.

Shankar B, Naidoo J.

J Thorac Dis. 2018 Nov;10(Suppl 33):S4034-S4037. doi: 10.21037/jtd.2018.09.46. No abstract available.

14.

Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer.

Phallen J, Leal A, Woodward BD, Forde PM, Naidoo J, Marrone KA, Brahmer JR, Fiksel J, Medina JE, Cristiano S, Palsgrove DN, Gocke CD, Bruhm DC, Keshavarzian P, Adleff V, Weihe E, Anagnostou V, Scharpf RB, Velculescu VE, Husain H.

Cancer Res. 2019 Mar 15;79(6):1204-1213. doi: 10.1158/0008-5472.CAN-18-1082. Epub 2018 Dec 20.

15.

Correction to CAN-Mediated Oxidations for the Synthesis of Xanthones and Related Products.

Johnson MM, Naidoo JM, Fernandes MA, Mmutlane EM, van Otterlo WAL, de Koning CB.

J Org Chem. 2019 Jan 4;84(1):472. doi: 10.1021/acs.joc.8b02352. Epub 2018 Dec 13. No abstract available.

PMID:
30543436
16.

Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

Anagnostou V, Forde PM, White JR, Niknafs N, Hruban C, Naidoo J, Marrone K, Sivakumar IKA, Bruhm DC, Rosner S, Phallen J, Leal A, Adleff V, Smith KN, Cottrell TR, Rhymee L, Palsgrove DN, Hann CL, Levy B, Feliciano J, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Isbell JM, Sauter JL, Taube J, Scharpf RB, Karchin R, Pardoll DM, Chaft JE, Hellmann MD, Brahmer JR, Velculescu VE.

Cancer Res. 2019 Mar 15;79(6):1214-1225. doi: 10.1158/0008-5472.CAN-18-1127. Epub 2018 Dec 12.

17.

An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition.

Naidoo J, Dykema A, D'Alessio F.

J Clin Invest. 2019 Jan 2;129(1):75-77. doi: 10.1172/JCI125800. Epub 2018 Dec 10.

18.

Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy.

Suresh K, Psoter KJ, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, Feliciano JL, Brahmer JR, Feller-Kopman D, Lerner AD, Lee H, Yarmus L, Hales RK, D'Alessio F, Danoff SK, Naidoo J.

J Thorac Oncol. 2019 Mar;14(3):494-502. doi: 10.1016/j.jtho.2018.11.016. Epub 2018 Nov 30.

PMID:
30503891
19.

Stakeholders' experiences in implementation of rapid changes to the South African prevention of mother-to-child transmission programme.

Chiya HW, Naidoo JR, Ncama BP.

Afr J Prim Health Care Fam Med. 2018 Nov 15;10(1):e1-e10. doi: 10.4102/phcfm.v10i1.1788.

20.

Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.

Moseley KF, Naidoo J, Bingham CO, Carducci MA, Forde PM, Gibney GT, Lipson EJ, Shah AA, Sharfman WH, Cappelli LC.

J Immunother Cancer. 2018 Oct 11;6(1):104. doi: 10.1186/s40425-018-0417-8.

21.

Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.

Suresh K, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, Feliciano JL, Brahmer JR, Feller-Kopman D, Lerner AD, Lee H, Yarmus L, D'Alessio F, Hales RK, Lin CT, Psoter KJ, Danoff SK, Naidoo J.

J Thorac Oncol. 2018 Dec;13(12):1930-1939. doi: 10.1016/j.jtho.2018.08.2035. Epub 2018 Sep 26.

PMID:
30267842
22.

Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.

Suresh K, Naidoo J, Lin CT, Danoff S.

Chest. 2018 Dec;154(6):1416-1423. doi: 10.1016/j.chest.2018.08.1048. Epub 2018 Sep 4. Review.

PMID:
30189190
23.

Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses.

Luthra P, Naidoo J, Pietzsch CA, De S, Khadka S, Anantpadma M, Williams CG, Edwards MR, Davey RA, Bukreyev A, Ready JM, Basler CF.

Antiviral Res. 2018 Oct;158:288-302. doi: 10.1016/j.antiviral.2018.08.012. Epub 2018 Aug 23.

PMID:
30144461
24.

Viral Apoptosis Evasion via the MAPK Pathway by Use of a Host Long Noncoding RNA.

Barichievy S, Naidoo J, Boullé M, Scholefield J, Parihar SP, Coussens AK, Brombacher F, Sigal A, Mhlanga MM.

Front Cell Infect Microbiol. 2018 Aug 3;8:263. doi: 10.3389/fcimb.2018.00263. eCollection 2018.

25.

Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer.

Wills B, Brahmer JR, Naidoo J.

Curr Treat Options Oncol. 2018 Aug 13;19(9):46. doi: 10.1007/s11864-018-0562-9. Review.

PMID:
30101402
26.

Extensive Transduction and Enhanced Spread of a Modified AAV2 Capsid in the Non-human Primate CNS.

Naidoo J, Stanek LM, Ohno K, Trewman S, Samaranch L, Hadaczek P, O'Riordan C, Sullivan J, San Sebastian W, Bringas JR, Snieckus C, Mahmoodi A, Mahmoodi A, Forsayeth J, Bankiewicz KS, Shihabuddin LS.

Mol Ther. 2018 Oct 3;26(10):2418-2430. doi: 10.1016/j.ymthe.2018.07.008. Epub 2018 Jul 12.

PMID:
30057240
27.

Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer.

Elster N, Toomey S, Fan Y, Cremona M, Morgan C, Weiner Gorzel K, Bhreathnach U, Milewska M, Murphy M, Madden S, Naidoo J, Fay J, Kay E, Carr A, Kennedy S, Furney S, Mezynski J, Breathhnach O, Morris P, Grogan L, Hill A, Kennedy S, Crown J, Gallagher W, Hennessy B, Eustace A.

Ther Adv Med Oncol. 2018 Jul 13;10:1758835918778297. doi: 10.1177/1758835918778297. eCollection 2018.

28.

Preoperative contralateral lung radiation dose is associated with postoperative pulmonary toxicity in patients with locally advanced non-small cell lung cancer treated with trimodality therapy.

Guo W, Hui X, Alfaifi S, Anderson L, Robertson S, Hales R, Hu C, McNutt T, Broderick S, Naidoo J, Battafarano R, Yang S, Voong KR.

Pract Radiat Oncol. 2018 Jul - Aug;8(4):e239-e248. doi: 10.1016/j.prro.2018.01.004. Epub 2018 Jan 31.

PMID:
29960625
29.

The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity.

Danilova L, Anagnostou V, Caushi JX, Sidhom JW, Guo H, Chan HY, Suri P, Tam A, Zhang J, Asmar ME, Marrone KA, Naidoo J, Brahmer JR, Forde PM, Baras AS, Cope L, Velculescu VE, Pardoll DM, Housseau F, Smith KN.

Cancer Immunol Res. 2018 Aug;6(8):888-899. doi: 10.1158/2326-6066.CIR-18-0129. Epub 2018 Jun 12.

PMID:
29895573
30.

Rediagnosis of Lung Cancer as NUT Midline Carcinoma Based on Clues From Tumor Genomic Profiling.

Baras AS, Naidoo J, Hann CL, Illei PB, Reninger CW, Lauring J.

J Natl Compr Canc Netw. 2018 May;16(5):467-472. doi: 10.6004/jnccn.2017.7203.

PMID:
29752320
31.

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Zhang J, Caushi JX, Chan HY, Sidhom JW, Scharpf RB, White J, Gabrielson E, Wang H, Rosner GL, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM.

N Engl J Med. 2018 May 24;378(21):1976-1986. doi: 10.1056/NEJMoa1716078. Epub 2018 Apr 16.

32.

Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen.

Cappelli LC, Brahmer JR, Forde PM, Le DT, Lipson EJ, Naidoo J, Zheng L, Bingham CO 3rd, Shah AA.

Semin Arthritis Rheum. 2018 Dec;48(3):553-557. doi: 10.1016/j.semarthrit.2018.02.011. Epub 2018 Mar 22.

PMID:
29573850
33.

Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.

Chen L, Douglass J, Kleinberg L, Ye X, Marciscano AE, Forde PM, Brahmer J, Lipson E, Sharfman W, Hammers H, Naidoo J, Bettegowda C, Lim M, Redmond KJ.

Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):916-925. doi: 10.1016/j.ijrobp.2017.11.041. Epub 2017 Dec 5.

PMID:
29485071
34.

Metabolomics of tomato xylem sap during bacterial wilt reveals Ralstonia solanacearum produces abundant putrescine, a metabolite that accelerates wilt disease.

Lowe-Power TM, Hendrich CG, von Roepenack-Lahaye E, Li B, Wu D, Mitra R, Dalsing BL, Ricca P, Naidoo J, Cook D, Jancewicz A, Masson P, Thomma B, Lahaye T, Michael AJ, Allen C.

Environ Microbiol. 2018 Apr;20(4):1330-1349. doi: 10.1111/1462-2920.14020. Epub 2017 Dec 22.

35.

Pneumonitis From Anti-PD-1/ PD-L1 Therapy.

Balaji A, Verde F, Suresh K, Naidoo J.

Oncology (Williston Park). 2017 Oct 15;31(10):739-46, 754.

36.

A systemic review of tuberculosis with HIV coinfection in children.

Naidoo J, Mahomed N, Moodley H.

Pediatr Radiol. 2017 Sep;47(10):1269-1276. doi: 10.1007/s00247-017-3895-9. Epub 2017 Aug 29. Review.

PMID:
29052773
37.

The next frontier in non-small cell lung cancer: synergizing radiation therapy and immune checkpoint blockade.

Voong KR, Naidoo J, Ettinger DS.

Clin Adv Hematol Oncol. 2017 Aug;15(8):615-625. Review.

PMID:
28949949
38.

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.

Arbour KC, Naidoo J, Steele KE, Ni A, Moreira AL, Rekhtman N, Robbins PB, Karakunnel J, Rimner A, Huang J, Riely GJ, Hellmann MD.

PLoS One. 2017 Aug 3;12(8):e0182665. doi: 10.1371/journal.pone.0182665. eCollection 2017.

39.

Lnc-ing inflammation to disease.

Magagula L, Gagliardi M, Naidoo J, Mhlanga M.

Biochem Soc Trans. 2017 Aug 15;45(4):953-62. doi: 10.1042/BST20160377. Epub 2017 Jul 7. Review.

PMID:
28687714
40.

Mapping evidence of interventions and strategies to bridge the gap in the implementation of the prevention of mother-to-child transmission of HIV programme policy in sub-Saharan countries: A scoping review.

Ngidi WH, Naidoo JR, Ncama BP, Luvuno ZPB, Mashamba-Thompson TP.

Afr J Prim Health Care Fam Med. 2017 May 29;9(1):e1-e10. doi: 10.4102/phcfm.v9i1.1368. Review.

41.

Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade.

Naidoo J, Cappelli LC, Forde PM, Marrone KA, Lipson EJ, Hammers HJ, Sharfman WH, Le DT, Baer AN, Shah AA, Albayda J, Manno RL, Haque U, Gutierrez AK, Bingham CO 3rd, Brahmer JR.

Oncologist. 2017 Jun;22(6):627-630. doi: 10.1634/theoncologist.2016-0390. Epub 2017 Jun 2. No abstract available.

42.

Spermidine promotes Bacillus subtilis biofilm formation by activating expression of the matrix regulator slrR.

Hobley L, Li B, Wood JL, Kim SH, Naidoo J, Ferreira AS, Khomutov M, Khomutov A, Stanley-Wall NR, Michael AJ.

J Biol Chem. 2017 Jul 21;292(29):12041-12053. doi: 10.1074/jbc.M117.789644. Epub 2017 May 25.

43.

A theory for aftercare of human trafficking survivors for nursing practice in low resource settings.

Curran RL, Naidoo JR, Mchunu G.

Appl Nurs Res. 2017 Jun;35:82-85. doi: 10.1016/j.apnr.2017.03.002. Epub 2017 Mar 16.

PMID:
28532733
44.
45.

Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.

Antczak MI, Zhang Y, Wang C, Doran J, Naidoo J, Voruganti S, Williams NS, Markowitz SD, Ready JM.

J Med Chem. 2017 May 11;60(9):3979-4001. doi: 10.1021/acs.jmedchem.7b00271. Epub 2017 Apr 25.

46.

Reply to M. Nishino et al.

Naidoo J, Iyriboz T, Cunningham J, Hellmann MD.

J Clin Oncol. 2017 May 10;35(14):1629-1630. doi: 10.1200/JCO.2016.71.6639. Epub 2017 Feb 6. No abstract available.

PMID:
28165907
47.

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, Hruban C, Guthrie VB, Rodgers K, Naidoo J, Kang H, Sharfman W, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Zahnow CA, Baylin SB, Scharpf RB, Brahmer JR, Karchin R, Pardoll DM, Velculescu VE.

Cancer Discov. 2017 Mar;7(3):264-276. doi: 10.1158/2159-8290.CD-16-0828. Epub 2016 Dec 28.

48.

Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment.

Cappelli LC, Naidoo J, Bingham CO 3rd, Shah AA.

Immunotherapy. 2017 Jan;9(1):5-8. doi: 10.2217/imt-2016-0117. No abstract available.

49.

The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.

Li BT, Barnes TA, Chan DL, Naidoo J, Lee A, Khasraw M, Marx GM, Kris MG, Clarke SJ, Drilon A, Rudin CM, Pavlakis N.

Lung Cancer. 2016 Dec;102:21-27. doi: 10.1016/j.lungcan.2016.10.004. Epub 2016 Oct 17.

50.

Optimizing the Delivery of Antineoplastic Therapies to the Central Nervous System.

Naidoo J, Panday H, Jackson S, Grossman SA.

Oncology (Williston Park). 2016 Nov 15;30(11):953-62. Review.

Supplemental Content

Loading ...
Support Center